Extended Data Fig. 4: Pathway alterations and the effects of genomic mutations on protein expression or phosphorylation in HBV-related early-stage HCC. | Nature

Extended Data Fig. 4: Pathway alterations and the effects of genomic mutations on protein expression or phosphorylation in HBV-related early-stage HCC.

From: Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma

Extended Data Fig. 4

a, Pathway alterations in HBV-related early-stage HCC. Left, alteration pathways in the tumours (n = 101) versus the non-tumour tissues (n = 98). Middle and right, alteration pathways in the tumour samples from the AFPhigh (n = 34) versus AFPlow (n = 67) and MVI+ (n = 22) versus MVI (n = 79) patients, respectively. P values are calculated by two-sided Fisher’s exact test based on the MSigDB database. Upregulated and downregulated pathways are indicated in red (right) and blue (left) bars. b, The activated pathways in the tumour samples (n = 92) are characterized by phospho-proteome data. The most significant pathways for the phospho-proteome are plotted on the x axis as the −log2 of the P value, compared with the proteome. P values are calculated by two-sided Fisher’s exact test based on the MSigDB database. c, Heat map of hyper-phosphorylated proteins across tumour (n = 92) and non-tumour (n = 92) tissues. The numbers of hyper- phosphorylation sites are shown for each protein and coloured in red, and proteins with no hyper-phosphorylation sites are coloured in white. Biological functions related to these proteins are denoted in the colour panel on the left. The samples are arranged in the same order as in Fig. 1. d, Heat map of dysregulated proteins by TSC1 and TSC2 mutation. The downstream substrate of mTOR, RPS6, was hyper-phosphorylated at the pS236, pS240 and pS244 sites. e, Heat map of dysregulated proteins by CTNNB1 mutation. The liver-related WNT targets GLUL and CYP1A2 were upregulated in tumour samples with CTNNB1 mutations.

Source data